PE/Cyanine7 anti-mouse CD62L Antibody

Pricing & Availability
Clone
MEL-14 (See other available formats)
Regulatory Status
RUO
Other Names
L-selectin, LECAM-1, Ly-22, LAM-1, MEL-14
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
MEL-14_PECy7_090707
C57BL/6 mouse splenocytes were stained with CD62L (clone MEL-14) PE/Cyanine7 (filled histogram) or rat IgG2a PE/Cyanine7 isotype control (open histogram).
  • MEL-14_PECy7_090707
    C57BL/6 mouse splenocytes were stained with CD62L (clone MEL-14) PE/Cyanine7 (filled histogram) or rat IgG2a PE/Cyanine7 isotype control (open histogram).
Compare all formats See PE/Cyanine7 spectral data
Cat # Size Price Quantity Check Availability Save
104417 25 µg 71€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
104418 100 µg 172€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD62L is a 74-95 kD glycoprotein also known as L-selectin, LECAM-1, Ly-22, LAM-1, and MEL-14. It is a member of the selectin family and is expressed on the majority of B and naïve T cells, a subset of memory T cells, monocytes, granulocytes, most thymocytes, and a subset of NK cells. CD62L is important in lymphocyte homing to high endothelial venules (HEV) in peripheral lymph nodes and leukocyte "rolling" on activated endothelium. CD62L also contributes to neutrophil emigration at inflammatory sites. CD62L is rapidly shed from lymphocytes and neutrophils upon cellular activation and the expression levels of CD62L (in conjunction with other markers) have been used to distinguish naïve, effector, and memory T cells. CD62L has been reported to interact with CD34, GlyCAM-1, and MAdCAM-1.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
C3H/eb mouse B lymphoma 38C-13
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine7 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation1-3, complement-dependent cytotoxicity4, in vivo and in vitro blocking of adhesion1-3,5, and immunohistochemical staining of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections6. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. Nos. 104457-104462).

Additional Product Notes
BioLegend is in the process of converting the name PE/Cy7 to PE/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our PE/Cyanine7 products. Please contact Technical Service if you have any questions.
Application References

(PubMed link indicates BioLegend citation)
  1. Gallatin WM, et al. 1983. Nature 304:30. (IP, Block)
  2. Siegelman MH, et al. 1990. Cell 61:611. (IP, Block)
  3. Lewinsohn DM, et al. 1987. J. Immunol. 138:4313. (IP, Block)
  4. Iwabuchi K, et al. 1991. Immunobiology 182:161. (CMCD)
  5. Pizcueta P, et al. 1994. Am. J. Pathol. 145:461.
  6. Reichert RA, et al. 1986. J. Immunol. 136:3535. (IHC, FC)
  7. Olver S, et al. 2006. Cancer Res. 66:571.
  8. Fukushima A, et al. 2006. Invest. Ophthalmol. Vis. Sci. 47:657. PubMed
  9. Benson MJ, et al. 2007. J. Exp. Med. doi:10.1084/jem.20070719. (FC) PubMed
  10. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed
  11. Lee JW, et al. 2006. Nature Immunol. 8:181.
  12. Shigeta A, et al. 2008. Blood 112:4915 (FC) PubMed
  13. de Vries VC, et al. 2009. Am. J. Transplant. 9:2270 PubMed
Product Citations
  1. Broadfield LA, et al. 2022. Mol Metab. 61:101498. PubMed
  2. Yue Y, et al. 2022. Nat Biomed Eng. 6:898. PubMed
  3. Zhu J, et al. 2022. Nat Commun. 13:7466. PubMed
  4. Weng S, et al. 2022. Front Immunol. 13:1025931. PubMed
  5. Cheng H, et al. 2023. Nat Metab. 5:314. PubMed
  6. Sun Y, et al. 2023. Cell Mol Life Sci. 80:63. PubMed
  7. Jiang L, et al. 2021. Nano Today. 36:. PubMed
  8. De Giovanni M, et al. 2022. Cell. 185:815. PubMed
  9. Ye ZW, et al. 2022. Cell Mol Immunol. 19:588. PubMed
  10. Bruggemann TR, et al. 2022. iScience. 25:105185. PubMed
  11. Oh–Hora M, et al. 2019. J Immunol. 202:2616. PubMed
  12. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  13. Gordan S, et al. 2020. Cell Reports. 29(10):3033-3046.e4.. PubMed
  14. Hu Y, et al. 2022. Front Immunol. 13:1022011. PubMed
  15. Barsheshet Y, et al. 2022. Int J Mol Sci. 23:. PubMed
  16. Wilson NG, et al. 2023. iScience. 26:105991. PubMed
  17. Falahat R, et al. 2023. Nat Commun. 14:1573. PubMed
  18. Ito M, et al. 2023. Sci Rep. 13:5939. PubMed
  19. Corria-Osorio J, et al. 2023. Nat Immunol. 24:869. PubMed
  20. van Os BW, et al. 2023. Front Cardiovasc Med. 10:1171764. PubMed
  21. Park HJ, et al. 2023. NPJ Vaccines. 8:84. PubMed
  22. Hu Y, et al. 2023. JCI Insight. 8:. PubMed
  23. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  24. Gerber AN, et al. 2021. Cell Rep. 37:109816. PubMed
  25. Bhatt K, et al. 2018. mSphere. 3:e00352. PubMed
  26. Uzhachenko RV, et al. 2021. Cell Reports. 35(1):108944. PubMed
  27. Gupta SS, et al. 2019. Cell Rep. 29:1862. PubMed
  28. Fernandes RA, et al. 2020. eLife. 9:e58463.. PubMed
  29. Ibrahim M, et al. 2016. J Evid Based Complementary Altern Med. 21: 171 - 176. PubMed
  30. Huang W, et al. 2014. J Immunol. 193:2267. PubMed
  31. Wu J, et al. 2020. Cell Reports. 31(1):107484. PubMed
  32. Kinder JM, et al. 2020. Cell Reports. 31(12):107784.. PubMed
  33. Tu X, et al. 2022. Nat Commun. 13:6977. PubMed
  34. Nguyen T, et al. 2017. Clin Transl Immunology. 10.1038/cti.2017.4. PubMed
  35. He C, et al. 2020. Clin Transl Med. 10:e39. PubMed
  36. Nagai Y, et al. 2019. Front Immunol. 10:174. PubMed
  37. LaFleur MW, et al. 2019. Nat Immunol. 20:1335. PubMed
  38. Wu J, et al. 2020. Sci Adv. 6:eaba3458. PubMed
  39. Gordon RA, et al. 2020. PLoS One. 15:e0226396. PubMed
  40. Li B, et al. 2015. Sci Rep. 5: 14793. PubMed
  41. Hirose M, et al. 2011. Biochem Biophys Res Commun. 414:437. PubMed
  42. Zhang H, et al. 2020. Cancer Cell. 37(1):37-54.e9.. PubMed
  43. Cheng K, et al. 2021. Nat Commun. 12:2041. PubMed
  44. Geiger R, et al. 2016. Cell. 167:829-842. PubMed
  45. He X, et al. 2021. Small. 17:e2007165. PubMed
  46. He X, et al. 2021. Adv Sci (Weinh). 8:e2103023. PubMed
  47. Canton J, et al. 2021. Nat Immunol. 22:140. PubMed
  48. Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed
  49. Snell LM, et al. 2018. Immunity. 49:678. PubMed
  50. Kim C, et al. 2019. Cell Rep. 29:2202. PubMed
  51. Hu Y, et al. 2022. J Nanobiotechnology. 20:417. PubMed
  52. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  53. He X, et al. 2022. Cancer Immunol Res. 10:314. PubMed
  54. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  55. Barsoumian HB, et al. 2020. J Immunother Cancer. 8:00. PubMed
  56. Burrack K, et al. 2015. J Immunol. 194:678. PubMed
  57. Stenström M, et al. 2010. Int Immunopharmacol. 10:837. PubMed
  58. Jing Y, et al. 2020. Sci Adv. 6:eaax9455. PubMed
  59. Place D, et al. 2017. PLoS One. 10.1371/journal.pone.0190384. PubMed
  60. Dey S, et al. 2020. J Immunother Cancer. 8:. PubMed
  61. DiPiazza AT, et al. 2021. Immunity. 54(8):1869-1882.e6. PubMed
  62. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  63. Masiuk KE, et al. 2019. Cell Stem Cell. 24:309. PubMed
  64. Horkova V, et al. 2020. Cell Reports. 30(5):1504-1514.e7.. PubMed
  65. Li G, et al. 2021. Front Oncol. 11:734593. PubMed
  66. Corbett KS, et al. 2020. Nature. 586:567. PubMed
  67. Morris AB, et al. 2020. Immunity. 52(1):136-150.e6.. PubMed
  68. Pham D, et al. 2019. Cell Rep. 29:1203. PubMed
  69. Yu X, et al. 2019. Nat Commun. 10:574. PubMed
  70. Guo S, et al. 2021. Sci Rep. 11:23745. PubMed
  71. Severance AL, et al. 2022. iScience. 25:104400. PubMed
  72. Robinett RA et al. 2018. Cell systems. 7(1):41-48 . PubMed
  73. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  74. Kretschmer L, et al. 2020. Nat Commun. 0.536805556. PubMed
  75. Hamaidi I, et al. 2020. Cell Metabolism. 32(3):420-436.e12. PubMed
  76. Martina M, et al. 2016. J Am Soc Nephrol. 27: 1113-1123. PubMed
  77. Jiang L, et al. 2020. Cell. 183(5):1219-1233.e18. PubMed
  78. Motwani MP, et al. 2018. JCI Insight. 3:e94463. PubMed
  79. He X, et al. 2021. J Immunother Cancer. 9:. PubMed
  80. Niven J, et al. 2019. Cell Rep. 28:21. PubMed
  81. Werner A, et al. 2021. iScience. 24:103076. PubMed
  82. Li J, et al. 2021. Cell Rep. 37:110124. PubMed
  83. Danzer H, et al. 2020. Elife. 9:00. PubMed
  84. Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
  85. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  86. Kohn M, et al. 2021. Front Immunol. 626627:12. PubMed
  87. Xu C, et al. 2021. Cell Reports. 35(11):109235. PubMed
  88. Kitamoto S, et al. 2020. Cell. 182(2):447-462.e14. PubMed
  89. Charlton J, et al. 2015. PLoS One. 10:119200. PubMed
  90. Seeling M, et al. 2013. Proc Natl Acad Sci U S A. 110:10729. PubMed
  91. Gonzalez MM, et al. 2021. J Clin Invest. 131:. PubMed
  92. Hu Y, et al. 2021. J Nanobiotechnology. 19:416. PubMed
  93. Angela M, et al. 2016. Nat Commun. 7:13683. PubMed
  94. Jaeger N, et al. 2020. Cell Rep. 33:108331. PubMed
  95. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
  96. Du Z, et al. 2020. J Allergy Clin Immunol. . PubMed
  97. Laczkó D, et al. 2020. Immunity. 53:724. PubMed
  98. BJ L, et al. 2017. J Exp Med . 10.1084/jem.20161461. PubMed
  99. Mohammed RN, et al. 2019. Sci Rep. 4.185416667. PubMed
RRID
AB_313102 (BioLegend Cat. No. 104417)
AB_313103 (BioLegend Cat. No. 104418)

Antigen Details

Structure
Selectin, 95 kD (neutrophils) or 74 kD (lymphocytes)
Distribution

Subsets of B and T cells, monocytes, granulocytes, subset of NK cells

Function
Lymphocyte homing to HEV, rolling on activated endothelium
Ligand/Receptor
CD34, GlyCAM-1, MAdCAM-1
Cell Type
B cells, Granulocytes, Monocytes, Neutrophils, NK cells, T cells, Tregs
Biology Area
Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity
Molecular Family
Adhesion Molecules, CD Molecules
Antigen References

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Kishimoto TK, et al. 1990. P. Natl. Acad. Sci. USA 87:2244.
3. Tedder TF, et al. 1995. J. Exp. Med. 181:2259.

Gene ID
20343 View all products for this Gene ID
UniProt
View information about CD62L on UniProt.org
Go To Top Version: 1    Revision Date: 11.30.2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account